Landfar Bio medicine Co

Landfar Bio medicine Co EBITDA per Share

The EBITDA per Share of Landfar Bio medicine Co (000504.SZ) as of Oct 18, 2026 is 0.09 CNY. In the previous year, EBITDA per Share was -0.04 CNY — a change of -353.29% (higher).

EBITDA per Share

0.09CNY

YoY

-353.29%

Last updated:

EBITDA per Share of Landfar Bio medicine Co is 2025 0.09 CNY. EBITDA per Share of Landfar Bio medicine Co was 2024 -0.04 CNY. It decreases by -353.29% higher compared to the previous year.

The Landfar Bio medicine Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.06 CNY
Jan 1, 2019
0.10 CNY
Jan 1, 2020
0.16 CNY
Jan 1, 2021
-0.07 CNY
Jan 1, 2022
-0.07 CNY
Jan 1, 2023
-0.12 CNY
Jan 1, 2024
-0.04 CNY
Jan 1, 2025
0.09 CNY
The Landfar Bio medicine Co EBITDA per Share history
YEAREBITDA per ShareYoY
0.09CNY-353.29%
-0.04CNY-67.93%
-0.12CNY+63.87%
-0.07CNY-2.54%
-0.07CNY-143.82%
0.16CNY+65.74%
0.10CNY-274.14%
-0.06CNY-48.11%
-0.11CNY-222.99%
0.09CNY-227.66%
-0.07CNY+24.50%
-0.06CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Landfar Bio medicine Co Stock analysis

What does Landfar Bio medicine Co do? Landfar Bio medicine Co Ltd, listed on the Shenzhen Stock Exchange under ticker 000504.SZ, operates as a biotechnology company based in Changsha, China. The company went public on December 8, 1992, and currently employs 512 people. Its primary business activities include the manufacture and sale of pharmaceutical products, with a focus on biomedical services such as stem cell storage, technical services, and research into stem cell treatments. Additionally, the company engages in medical instrument purchasing and sales. Landfar Bio medicine also operates within the energy conservation and environmental protection sector, offering services like contract energy management through energy management companies (EMCs), build-transfer (BT) projects, product sales, and sewage treatment solutions. The firm primarily serves the domestic Chinese market, with no indication of significant international operations. Its official website is http://www.nhbiogroup.com/, though the source description provided contains conflicting information referring to the company as NanHua Bio-medicine Co., Ltd., which may be an error or an alternate name. The company’s industry classification is biotechnology within the healthcare sector, reflecting its focus on innovative medical solutions and environmental sustainability initiatives. Landfar Bio medicine Co Ltd maintains a presence in Changsha, Hunan, and its operations are centered around pharmaceuticals, biomedical services, and environmental technologies. Landfar Bio medicine Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Landfar Bio medicine Co stock

EBITDA per Share of Landfar Bio medicine Co is 0.09 CNY in 2025.

EBITDA per Share of Landfar Bio medicine Co changed from -0.04 CNY to 0.09 CNY, representing a -353.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Landfar Bio medicine Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Landfar Bio medicine Co

All Key Metrics — Landfar Bio medicine Co